To the Editor:
We appreciate the comments from Jourde-Chiche and Daugas1 on our study evaluating the frequency of renal flares in patients with proliferative lupus nephritis in whom the dose of mycophenolate mofetil (MMF) was reduced during remission maintenance therapy. They raise the question whether hydroxychloroquine (HCQ) cotreatment can influence the observed flare rates.
An association of HCQ withdrawal with exacerbations of renal disease in patients with lupus has been described by Tsakonas, et al2 …
Address correspondence to Dr. Laskari; E-mail: katerina_laskari{at}yahoo.gr